GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca PLC (CHIX:AZNl) » Definitions » Cyclically Adjusted PB Ratio

AstraZeneca (CHIX:AZNL) Cyclically Adjusted PB Ratio : 8.73 (As of Sep. 22, 2024)


View and export this data going back to 2009. Start your Free Trial

What is AstraZeneca Cyclically Adjusted PB Ratio?

As of today (2024-09-22), AstraZeneca's current share price is £117.88. AstraZeneca's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2024 was £13.51. AstraZeneca's Cyclically Adjusted PB Ratio for today is 8.73.

The historical rank and industry rank for AstraZeneca's Cyclically Adjusted PB Ratio or its related term are showing as below:

CHIX:AZNl' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 4.01   Med: 6.78   Max: 10.1
Current: 8.74

During the past years, AstraZeneca's highest Cyclically Adjusted PB Ratio was 10.10. The lowest was 4.01. And the median was 6.78.

CHIX:AZNl's Cyclically Adjusted PB Ratio is ranked worse than
92.27% of 569 companies
in the Drug Manufacturers industry
Industry Median: 1.77 vs CHIX:AZNl: 8.74

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

AstraZeneca's adjusted book value per share data for the three months ended in Jun. 2024 was £20.033. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is £13.51 for the trailing ten years ended in Jun. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


AstraZeneca Cyclically Adjusted PB Ratio Historical Data

The historical data trend for AstraZeneca's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca Cyclically Adjusted PB Ratio Chart

AstraZeneca Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.33 7.32 8.24 9.33 8.20

AstraZeneca Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.95 8.70 8.20 8.11 9.17

Competitive Comparison of AstraZeneca's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - General subindustry, AstraZeneca's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AstraZeneca's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where AstraZeneca's Cyclically Adjusted PB Ratio falls into.



AstraZeneca Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

AstraZeneca's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=117.88/13.51
=8.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AstraZeneca's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2024 is calculated as:

For example, AstraZeneca's adjusted Book Value per Share data for the three months ended in Jun. 2024 was:

Adj_Book=Book Value per Share/CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=20.033/133.0000*133.0000
=20.033

Current CPI (Jun. 2024) = 133.0000.

AstraZeneca Quarterly Data

Book Value per Share CPI Adj_Book
201409 9.939 100.000 13.219
201412 9.929 99.900 13.219
201503 8.964 99.600 11.970
201506 9.287 100.100 12.339
201509 8.949 100.200 11.878
201512 9.771 100.400 12.944
201603 8.180 100.400 10.836
201606 7.530 101.000 9.916
201609 7.864 101.500 10.305
201612 9.404 102.200 12.238
201703 8.310 102.700 10.762
201706 8.424 103.500 10.825
201709 8.132 104.300 10.370
201712 8.814 105.000 11.164
201803 7.301 105.100 9.239
201806 7.507 105.900 9.428
201809 7.208 106.600 8.993
201812 7.774 107.100 9.654
201903 6.066 107.000 7.540
201906 8.149 107.900 10.045
201909 7.492 108.400 9.192
201912 7.633 108.500 9.357
202003 6.637 108.600 8.128
202006 7.451 108.800 9.108
202009 7.174 109.200 8.738
202012 8.854 109.400 10.764
202103 7.925 109.700 9.608
202106 8.514 111.400 10.165
202109 18.677 112.400 22.100
202112 19.059 114.700 22.100
202203 17.801 116.500 20.322
202206 18.830 120.500 20.783
202209 20.021 122.300 21.773
202212 19.620 125.300 20.826
202303 19.028 126.800 19.958
202306 19.108 129.400 19.640
202309 19.392 130.100 19.824
202312 19.948 130.500 20.330
202403 19.010 131.600 19.212
202406 20.033 133.000 20.033

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


AstraZeneca  (CHIX:AZNl) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


AstraZeneca Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of AstraZeneca's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


AstraZeneca Business Description

Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its revenue.

AstraZeneca Headlines

No Headlines